[{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marinomed Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"PALADIN LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Paladin Labs","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Paladin Labs"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanderbilt University Medical Center \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Vanderbilt University Medical Center \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Beth Israel Deaconess Medical Center \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Chang Gung Memorial Hospital","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chang Gung Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chang Gung Memorial Hospital \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Chang Gung Memorial Hospital \/ Astellas Pharma"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"National Taiwan University Hospital \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.25,"dosageForm":"Capsule","sponsorNew":"Mankind Pharma \/ Panacea Biotec Limited","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Panacea Biotec Limited"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Astellas Pharma"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Chong Kun Dang Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SOUTH KOREA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Chong Kun Dang Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Chong Kun Dang Pharm"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Raytone Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Raytone Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Raytone Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Raytone Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Nantes University Hospital \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"Nantes University Hospital \/ Chiesi Group"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Tours \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Tours \/ Astellas Pharma"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Tours \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Tours \/ Astellas Pharma"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Sandoz B2B","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Sandoz B2B"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule, Prolonged Release","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"ITALY","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Cromsource","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ITALY","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Cromsource","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Cromsource"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Rabin Medical Center","sponsor":"Astellas Pharma | Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase III","graph3":"Rabin Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rabin Medical Center \/ Astellas Pharma | Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Rabin Medical Center \/ Astellas Pharma | Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Auritec Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Auritec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection, Sustained Release","sponsorNew":"Auritec Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Auritec Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Davis \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Davis \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of Southern California","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Southern California \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"University of Colorado, Denver \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"University of Colorado, Denver \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Loyola University","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Loyola University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loyola University \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Loyola University \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Northwestern University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Undisclosed","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Northwestern University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unity Health Toronto \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ US Department of Defense"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"PALADIN LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"University of British Columbia \/ Paladin Labs","highestDevelopmentStatusID":"11","companyTruncated":"University of British Columbia \/ Paladin Labs"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ Astellas Pharma"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ Astellas Pharma"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Simon Fraser University | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Simon Fraser University | Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of British Columbia \/ Simon Fraser University | Astellas Pharma"},{"orgOrder":0,"company":"University of Saskatchewan","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Saskatchewan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Saskatchewan \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Saskatchewan \/ Astellas Pharma"},{"orgOrder":0,"company":"Food and Drug Administration","sponsor":"BioPharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase I","graph3":"Food and Drug Administration","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Food and Drug Administration \/ BioPharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Food and Drug Administration \/ BioPharma Services"},{"orgOrder":0,"company":"BNS Ophthalmics","sponsor":"BioNanoSim","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"BNS Ophthalmics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BNS Ophthalmics \/ BioNanoSim","highestDevelopmentStatusID":"4","companyTruncated":"BNS Ophthalmics \/ BioNanoSim"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cincinnati \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Cincinnati \/ Astellas Pharma"},{"orgOrder":0,"company":"Temple University","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Temple University \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Temple University \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Albert Einstein Healthcare Network \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Medical University of South Carolina \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of South Carolina \/ Astellas Pharma"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Neurology","graph2":"Phase IV","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of South Carolina \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Vanderbilt University Medical Center \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Vanderbilt University Medical Center \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Methodist Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II","graph3":"Methodist Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Methodist Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Methodist Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"The Methodist Hospital Research Institute","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"The Methodist Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The Methodist Hospital Research Institute \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"The Methodist Hospital Research Institute \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Sentara Norfolk General Hospital","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Sentara Norfolk General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sentara Norfolk General Hospital \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Sentara Norfolk General Hospital \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medical College of Wisconsin \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Medical College of Wisconsin \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase IV","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cedars-Sinai \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Cedars-Sinai \/ Astellas Pharma"},{"orgOrder":0,"company":"Columbia University","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Columbia University \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Lipella Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Urology","graph2":"Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cook MyoSite \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cook MyoSite \/ Lipella Pharmaceuticals"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Novotech"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"8","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz B2B"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Cedars-Sinai \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Linical","sponsor":"Astellas Pharma | National Cancer Center, Korea","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Linical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linical \/ Astellas Pharma | National Cancer Center, Korea","highestDevelopmentStatusID":"11","companyTruncated":"Linical \/ Astellas Pharma | National Cancer Center, Korea"},{"orgOrder":0,"company":"Linical","sponsor":"Asan Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Linical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Linical \/ Asan Medical Center","highestDevelopmentStatusID":"11","companyTruncated":"Linical \/ Asan Medical Center"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"National Institutes of Health | The V Foundation for Cancer Research | National Cancer Institute | ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ National Institutes of Health | The V Foundation for Cancer Research | National Cancer Institute | ImmunityBio","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ National Institutes of Health | The V Foundation for Cancer Research | National Cancer Institute | ImmunityBio"},{"orgOrder":0,"company":"Columbia University","sponsor":"Pfizer Inc | Cornell University","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Pfizer Inc | Cornell University","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Pfizer Inc | Cornell University"},{"orgOrder":0,"company":"Veloxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase III","graph3":"Veloxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veloxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veloxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Norman Muirhead","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Norman Muirhead","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Norman Muirhead \/ Astellas Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Norman Muirhead \/ Astellas Pharma"},{"orgOrder":0,"company":"Edward Geissler","sponsor":"Chiesi Group | Excelya","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Edward Geissler","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edward Geissler \/ Chiesi Group | Excelya","highestDevelopmentStatusID":"11","companyTruncated":"Edward Geissler \/ Chiesi Group | Excelya"},{"orgOrder":0,"company":"Edward Geissler","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Edward Geissler","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Edward Geissler \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"Edward Geissler \/ Chiesi Group"},{"orgOrder":0,"company":"Simon Tremblay, PharmD, PhD","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Simon Tremblay, PharmD, PhD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Simon Tremblay, PharmD, PhD \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Simon Tremblay, PharmD, PhD \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Heleen Grootjans","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase III","graph3":"Heleen Grootjans","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Heleen Grootjans \/ Chiesi Group","highestDevelopmentStatusID":"10","companyTruncated":"Heleen Grootjans \/ Chiesi Group"},{"orgOrder":0,"company":"Roy D. Bloom, MD","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Roy D. Bloom, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Roy D. Bloom, MD \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Roy D. Bloom, MD \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Roberto Gedaly","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Roberto Gedaly","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roberto Gedaly \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Roberto Gedaly \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Klemens Budde","sponsor":"Charite University, Berlin, Germany | European Renal Association - European Dialysis and Transplant Association | European Kidney Transplant Association | DESCARTES Working Group On Transplantation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Klemens Budde","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Klemens Budde \/ Charite University, Berlin, Germany | European Renal Association - European Dialysis and Transplant Association | European Kidney Transplant Association | DESCARTES Working Group On Transplantation","highestDevelopmentStatusID":"11","companyTruncated":"Klemens Budde \/ Charite University, Berlin, Germany | European Renal Association - European Dialysis and Transplant Association | European Kidney Transplant Association | DESCARTES Working Group On Transplantation"},{"orgOrder":0,"company":"Kim Seoung-Hoon","sponsor":"Astellas Pharma | Linical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase IV","graph3":"Kim Seoung-Hoon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kim Seoung-Hoon \/ Astellas Pharma | Linical","highestDevelopmentStatusID":"11","companyTruncated":"Kim Seoung-Hoon \/ Astellas Pharma | Linical"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"||High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||IL-15-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"||Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Orca-T","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orca Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Orca Bio \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Tacrolimus
Details :
The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were...
Details :
Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Details :
Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
RTP-008 is developed based on iSus® bioabsorbable sustained-release drug delivery platform, is a novel ophthalmic tacrolimus designed to address the complexities of dry eye disease.
Details :
Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.
Details :
Tacrolimus is a macrolide antibiotic with immunosuppressive properties, binds to FK506 binding protein inhibiting calcineurin phosphatase, received approval for organ rejection.
Details :
Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Sponsor :
Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute
Details :
Tacrolimus is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft vs Host Disease.
Sponsor :
Blood and Marrow Transplant Clinical Trials Network | National Institutes of Health | National Heart, Lung, and Blood Institute | National Cancer Institute
Reset All
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
